CoCensys Appoints Lowell Sears, former CFO of Amgen, to Board of Directors.IRVINE, Calif.--(HealthWire)--November 10, 1994--CoCensys, Inc. (Nasdaq: COCN COCN Certified Ostomy Care Nurse ) announced today that it has appointed Lowell E. Sears to its Board of Directors, increasing the CoCensys board to eight members. Sears, age 43, is a private investor involved in portfolio management and life sciences venture capital. From 1988 to April of this year, Sears was chief financial officer of Amgen Inc. In addition to his role as CFO See Chief Financial Officer. of Amgen, from 1992 to 1994, Sears served as senior vice president, responsible for the Asia-Pacific region, establishing development, marketing and sales capabilities in a number of countries, including Japan and the People's Republic of China. He also served as CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. for the joint venture Kirin-Amgen Inc. While at Amgen, Sears built the financial organization which took the company from a small R&D firm with no pharmaceutical sales to a leading multinational pharmaceutical company with nearly $1.4 billion in revenues. Also during this period, he raised more than $700 million in public and private market financings, as well as negotiating numerous strategic alliances and product licenses. "We are delighted to add Lowell Sears to CoCensys' Board of Directors," said Robert G. McNeil, Ph.D., chairman of CoCensys. "We are confident that his expertise in the biopharmaceutical field and his experience with Amgen will strengthen the Company's leadership opportunities in the CNS See Continuous net settlement. CNS See continuous net settlement (CNS). arena." "We are pleased to welcome Lowell Sears to our board. His financial expertise in the life sciences sector will prove invaluable as we grow CoCensys and continue the development of our ground-breaking CNS drugs," commented Daniel L. Korpolinski, president and CEO of CoCensys. CoCensys is a biopharmaceutical company that discovers, develops and markets products to treat neurological and psychiatric disorders. The company's product development programs focus on two novel, proprietary classes of compounds: Epalons, to treat petit mal epilepsy Noun 1. petit mal epilepsy - epilepsy characterized by paroxysmal attacks of brief clouding of consciousness (and possibly other abnormalities); "she has been suffering from petit mal since childhood" epilepsia minor, petit mal , anxiety and sleep disorders Sleep Disorders Definition Sleep disorders are a group of syndromes characterized by disturbance in the patient's amount of sleep, quality or timing of sleep, or in behaviors or physiological conditions associated with sleep. , and Glystasins, to treat stroke and head trauma, chronic pain and grand mal epilepsy Noun 1. grand mal epilepsy - epilepsy in which the attacks involve loss of consciousness and tonic spasms of the musculature followed by generalized jerking epilepsia major, generalized epilepsy, grand mal . CONTACT: Daniel L. Korpolinski
President and CEO
CoCensys, Inc.
714/753-6100
Karen L. Bergman (Media Relations)
Lilian S. Stern (Investor Relations)
Burns McClellan
212/505-1919
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion